XXXX for @entity1540 : short- and long-term effects.

@entity1 @entity10719 @entity1540 @entity299
The safety and efficacy of oral @entity10719 therapy for the suppression of @entity1540 ( @entity1540 ) were assessed in two clinical trials pooled for analysis. Thirty-two @entity1 suffering from @entity299 , who had experienced an average of greater than or equal to 10 @entity1540 /h (range 14 to 996 three times a day) on Holter monitoring during a 24-hour baseline study period, were given @entity10719 (100 mg three times a day to 400 mg four times a day) over 4 weeks. Three @entity1 were withdrawn from the study for administrative reasons, and four @entity1 were excluded from the efficacy analysis. Of the 25 remaining @entity1 (24 @entity1 , 1 @entity1 ; mean age 56 years, range 37 to 69), 18 (72%) experienced some reduction in @entity1540 from the second through the fourth week of therapy. Eleven @entity1 (44%) experienced clinically significant reductions (greater than or equal to 75%) in @entity1540 . The onset of the antiarrhythmic effect of @entity10719 was within 7 days of administration. Transient mild to moderate side effects were noted in eight @entity1 . Significant correlations (p less than 0.001) were observed between the mean daily dose of @entity10719 and (1) mean blood levels, (2) reduction in @entity1540 , and (3) reduction in resting heart rate. The average daily dose of @entity10719 ranged from 304 to 1060 mg. In nine @entity1 receiving @entity10719 in a 12-month open-label extension, both efficacy and safety were maintained. This study confirms that oral @entity10719 therapy in both safe and efficacious for suppressing @entity1540 in @entity1 with @entity299 .
